Published in J Biol Chem on July 17, 2006
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci (2012) 4.96
Metastasis: recent discoveries and novel treatment strategies. Lancet (2007) 3.93
Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20
Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood (2009) 2.73
Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res (2012) 1.55
Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer (2008) 1.49
BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem (2009) 1.43
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis (2007) 1.29
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene (2010) 1.17
Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer. J Exp Clin Cancer Res (2009) 1.07
Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia (2010) 1.07
YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther (2012) 1.07
Therapeutic effects of astragaloside IV on myocardial injuries: multi-target identification and network analysis. PLoS One (2012) 1.07
Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer (2010) 1.06
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One (2012) 1.05
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther (2010) 1.03
Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer (2011) 1.01
Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther Onkol (2009) 1.01
HIF-1alpha and HIF-2alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle. J Physiol (2007) 0.96
Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. Int J Nanomedicine (2012) 0.96
Prokineticin-1: a novel mediator of the inflammatory response in third-trimester human placenta. Endocrinology (2008) 0.96
CypA, a gene downstream of HIF-1α, promotes the development of PDAC. PLoS One (2014) 0.95
Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer. PLoS One (2013) 0.93
Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. Br J Cancer (2008) 0.92
OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma. BMC Cancer (2013) 0.92
Hepatocellular carcinoma: Where are we? World J Exp Med (2016) 0.92
Hypoxia increases Annexin A2 expression in osteoblastic cells via VEGF and ERK. Bone (2010) 0.90
Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. BMC Cancer (2013) 0.89
Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis (2008) 0.87
An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res (2013) 0.87
Betacellulin inhibits osteogenic differentiation and stimulates proliferation through HIF-1alpha. Cell Tissue Res (2010) 0.86
Exosomal Proteome Profiling: A Potential Multi-Marker Cellular Phenotyping Tool to Characterize Hypoxia-Induced Radiation Resistance in Breast Cancer. Proteomes (2013) 0.86
Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles. Small (2013) 0.86
EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms. Int J Cancer (2010) 0.86
HIF-1α knockdown by miRNA decreases survivin expression and inhibits A549 cell growth in vitro and in vivo. Int J Mol Med (2013) 0.85
Activated epidermal growth factor receptor in ovarian cancer. Cancer Treat Res (2009) 0.84
Oxygen-mediated endocytosis in cancer. J Cell Mol Med (2010) 0.84
Role of Hypoxia-inducible factor-1 alpha and Survivin in colorectal carcinoma progression. Int J Colorectal Dis (2008) 0.84
Insulin Protects Cardiac Myocytes from Doxorubicin Toxicity by Sp1-Mediated Transactivation of Survivin. PLoS One (2015) 0.83
MiR199b suppresses expression of hypoxia-inducible factor 1α (HIF-1α) in prostate cancer cells. Int J Mol Sci (2013) 0.83
The real face of HIF1α in the tumor process. Cell Cycle (2012) 0.83
Integration of CNS survival and differentiation by HIF2α. Cell Death Differ (2011) 0.83
NS398 induces apoptosis in non-small cell lung cancer cells. J Cancer Res Clin Oncol (2011) 0.81
Association between survivin -31G > C promoter polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet (2012) 0.81
YM155 reverses rapamycin resistance in renal cancer by decreasing survivin. J Cancer Res Clin Oncol (2014) 0.81
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. Clin Breast Cancer (2015) 0.80
Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies. J Cancer Res Clin Oncol (2014) 0.80
Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors. J Pharmacol Exp Ther (2014) 0.79
Hypoxia-inducible factor-1α enhances the malignant phenotype of multicellular spheroid HeLa cells in vitro. Oncol Lett (2010) 0.79
Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases. Virchows Arch (2013) 0.79
SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α. Sci Rep (2015) 0.78
Pathophysiological mechanisms of death resistance in colorectal carcinoma. World J Gastroenterol (2015) 0.78
Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis. Clin Transl Oncol (2012) 0.78
EGFR signaling promotes β-cell proliferation and survivin expression during pregnancy. PLoS One (2014) 0.78
The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma. Int J Clin Exp Med (2015) 0.76
Yin Yang 1 regulates the transcriptional repression of Survivin. Biochem Biophys Res Commun (2014) 0.76
Multiplexed fluorescence imaging of tumor biomarkers in gene expression and protein levels for personalized and predictive medicine. Curr Mol Med (2009) 0.76
The twisted survivin connection to angiogenesis. Mol Cancer (2015) 0.76
Normoxic accumulation of HIF1α is associated with glutaminolysis. Clin Oral Investig (2016) 0.76
Expression characteristics of proteins of IGF-1R, p-Akt, and survivin in papillary thyroid carcinoma patients with type 2 diabetes mellitus. Medicine (Baltimore) (2017) 0.75
Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs (2016) 0.75
A ranking method for the concurrent learning of compounds with various activity profiles. J Cheminform (2015) 0.75
Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma. ISRN Surg (2012) 0.75
Helicobacter pylori Induced Phosphatidylinositol-3-OH Kinase/mTOR Activation Increases Hypoxia Inducible Factor-1α to Promote Loss of Cyclin D1 and G0/G1 Cell Cycle Arrest in Human Gastric Cells. Front Cell Infect Microbiol (2017) 0.75
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clin Cancer Res (2015) 0.75
Oxygen-carbon nanotubes as a chemotherapy sensitizer for paclitaxel in breast cancer treatment. PLoS One (2014) 0.75
Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway. Sci Rep (2017) 0.75
The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis. Cell Death Dis (2017) 0.75
Engineered myocardium model to study the roles of HIF-1α and HIF1A-AS1 in paracrine-only signaling under pathological level oxidative stress. Acta Biomater (2017) 0.75
EGF regulation of proximal tubule cell proliferation and VEGF-A secretion. Physiol Rep (2017) 0.75
HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression. Oncotarget (2017) 0.75
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
Validating survivin as a cancer therapeutic target. Nat Rev Cancer (2003) 5.73
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol (2001) 5.59
The EGF receptor family as targets for cancer therapy. Oncogene (2000) 5.44
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J (1998) 5.28
Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem (2001) 4.21
Structural basis for the inhibition of caspase-3 by XIAP. Cell (2001) 3.91
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res (2000) 3.24
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ (2001) 2.85
An IAP-IAP complex inhibits apoptosis. J Biol Chem (2004) 2.82
Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell (2001) 2.43
Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res (2003) 2.09
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol (2000) 1.79
Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem (2004) 1.73
BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene (2003) 1.73
Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem (1999) 1.59
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res (2005) 1.59
Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene (2000) 1.54
Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther (2001) 1.52
Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res (2005) 1.49
EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol (2003) 1.43
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res (2005) 1.22
Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res (2001) 1.17
Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther (2004) 1.11
EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp Mol Pathol (2005) 1.09
The EGF/ErbB receptor family and apoptosis. Growth Factors (2002) 1.04
EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat (1994) 1.03
EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat (2004) 0.99
Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol (2005) 0.98
EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res (1997) 0.95
Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer (2005) 0.92
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. Front Biosci (2005) 0.91
Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. Ann Oncol (2002) 0.87
What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer? Breast Cancer Res Treat (1994) 0.79
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol (2007) 7.33
In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol (2005) 3.92
In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol (2009) 3.21
Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res (2007) 2.54
Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15
Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res (2003) 2.09
Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res (2011) 2.08
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small (2009) 1.93
MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One (2011) 1.90
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal (2006) 1.87
Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res (2009) 1.86
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol (2004) 1.85
AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res (2007) 1.85
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun (2003) 1.82
Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity. J Biol Chem (2006) 1.78
MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res (2011) 1.77
Involvement of vascular peroxidase 1 in angiotensin II-induced vascular smooth muscle cell proliferation. Cardiovasc Res (2011) 1.70
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell (2009) 1.60
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal (2007) 1.58
Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J (2005) 1.56
PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol (2003) 1.49
Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res (2005) 1.49
Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol (2005) 1.47
Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology (2009) 1.47
ILK mediates actin filament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling. Oncogene (2005) 1.46
Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem (2004) 1.45
Synergistic antimicrotubule therapy for prostate cancer. Biochem Pharmacol (2010) 1.44
A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol (2012) 1.42
Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem (2002) 1.41
Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res (2006) 1.38
Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells. Toxicol Sci (2011) 1.34
Identification and characterization of VPO1, a new animal heme-containing peroxidase. Free Radic Biol Med (2008) 1.33
Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets (2013) 1.33
Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med (2006) 1.32
Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond) (2006) 1.32
Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer (2009) 1.31
MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One (2012) 1.31
Regulation of survivin by PI3K/Akt/p70S6K1 pathway. Biochem Biophys Res Commun (2010) 1.30
KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem (2006) 1.30
Quantification of the heterogeneity in breast cancer cell lines using whole-cell impedance spectroscopy. Clin Cancer Res (2007) 1.29
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano (2013) 1.28
Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis (2006) 1.25
Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials (2010) 1.25
Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics (2012) 1.24
Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr Cancer (2008) 1.20
MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle (2012) 1.20
trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res (2004) 1.18
Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis. Cancer Res (2008) 1.18
Superantigens and streptococcal toxic shock syndrome. Emerg Infect Dis (2003) 1.17
MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle (2013) 1.16
Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation. EMBO Rep (2012) 1.16
Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol Cell Biochem (2004) 1.15
Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production. Am J Respir Cell Mol Biol (2009) 1.14
Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials (2011) 1.14
Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis (2006) 1.14
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol (2006) 1.14
Nickel compounds act through phosphatidylinositol-3-kinase/Akt-dependent, p70(S6k)-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cells. Cancer Res (2004) 1.13
Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res (2008) 1.13
Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur J Immunol (2005) 1.10
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer (2005) 1.10
Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J Cell Physiol (2006) 1.10
Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res (2010) 1.10
Regulation of Tat acetylation and transactivation activity by the microtubule-associated deacetylase HDAC6. J Biol Chem (2011) 1.10
Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal (2007) 1.09
P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochem Biophys Res Commun (2010) 1.09
Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. PLoS One (2013) 1.09
Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. Cancer Res (2002) 1.09
The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol (2008) 1.08
Glucose up-regulates HIF-1 alpha expression in primary cortical neurons in response to hypoxia through maintaining cellular redox status. J Neurochem (2008) 1.08
Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of caveolin-1. J Biol Chem (2009) 1.08
Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol (2012) 1.07
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res (2010) 1.07
Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening. Semin Oncol (2011) 1.07
MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas. RNA (2013) 1.06
Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Chem Biol Drug Des (2009) 1.05
Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species. Free Radic Biol Med (2007) 1.05
p38 Signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. J Biol Chem (2002) 1.03
T₁-weighted ultrashort echo time method for positive contrast imaging of magnetic nanoparticles and cancer cells bound with the targeted nanoparticles. J Magn Reson Imaging (2011) 1.03
Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. Cell Cycle (2011) 1.02
Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway. Food Chem (2012) 1.02
An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene (2004) 1.02
Resident renal mononuclear phagocytes comprise five discrete populations with distinct phenotypes and functions. J Immunol (2013) 1.01
Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer (2011) 1.01
c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One (2010) 1.01
Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively. J Biol Chem (2004) 1.00
Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther (2007) 0.99
Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol (2005) 0.99
MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Mol Cell Biol (2011) 0.98
Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells. Clin Exp Metastasis (2006) 0.98
Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther (2008) 0.97
A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer (2010) 0.96
Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Cancer Cell Int (2010) 0.96